Tag
Alcohol-associated hepatitis (AH) carries high morbidity and mortality, with no approved therapies addressing both liver injury and alcohol misuse. This article explores integrated trial designs using composite endpoints combining liver and
Quantitative CT imaging offers valuable prognostic information and helps assess treatment response in patients with progressive pulmonary fibrosis, supporting better clinical trial outcomes and therapeutic decisions.
Emerging therapies have revolutionized first-line treatment in large B-cell lymphoma, but inconsistent trial designs and biomarker use create complexity. Harmonized strategies integrating biomarkers, pooled data, AI, and regulatory collabor
A multidisciplinary consensus provides practical, trial-design focused recommendations for testing systemic therapies around surgery or combined with locoregional treatment in hepatocellular carcinoma, emphasizing patient selection, endpoin
Combined analysis of the TETON-1 and TETON-2 trials confirms inhaled treprostinil significantly slows lung function decline, reduces clinical worsening and exacerbations, and improves quality of life in idiopathic pulmonary fibrosis over on
County-level social vulnerability significantly limits ovarian cancer clinical trial availability, underscoring structural inequities and the need for targeted strategies to improve trial access in vulnerable communities.
Phase 3 trials show satralizumab significantly improves proptosis, inflammation, and diplopia in thyroid eye disease with a favorable safety profile, marking a new therapeutic option targeting the IL-6 receptor pathway.
Aficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.
This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.
Drug-Induced Liver Injury (DILI) remains a pivotal challenge in drug development, with evolving drug modalities and clinical trial designs prompting updated regulatory perspectives from FDA specialists.
This review contrasts early- and late-phase gynecologic oncology trials, underscoring disparities in trial completion, publication, and racial/ethnic minority enrollment, highlighting the need to improve inclusivity and reporting.
A pilot program using former gynecologic oncology trial participants as patient ambassadors improved confidence and perceptions about clinical trials among trial-naïve patients, highlighting a feasible peer-education approach.
This study identifies that 30% of gynecologic cancer clinical trials fail to complete, with insufficient patient accrual as the leading cause, highlighting crucial factors like intervention type, initiation year, and geographic variations t
This review synthesizes evidence linking periodontitis-induced inflammation with clonal hematopoiesis, exploring implications for tumor metastasis, trial methodology, and microbiome-host crosstalk.
This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.
A comprehensive evidence-based synthesis of the REMAP-CAP trial and major international RCTs, demonstrating that ivermectin fails to improve clinical outcomes, survival, or organ support requirements in hospitalized and non-hospitalized COV
A culturally tailored educational intervention significantly improved clinical trial knowledge and self-efficacy among African American and Hispanic women, highlighting the potential of community partnerships to address disparities in gynec
A study reveals significant variability in ALSFRS-R analysis methods across 45 ALS trials, impacting treatment effect estimates and increasing false-positive risks, with implications for clinical decision-making and drug development.
Researchers developed and validated ADAPT-CEC, an artificial intelligence algorithm that can adjudicate cardiovascular events across different trial definitions. A hybrid approach combining AI with selective human review achieved 95.6% accu
This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintai
